Objectives: Inflammatory cytokines are involved in the development of mucous cell metaplasia and hyperplasia (MCM) in otitis media (OM). However, which cytokines play an essential role in the MCM of OM is not clear at the moment. Methods: In this study, we hypothesized that interleukin-10 (IL-10) played an indispensable role in the MCM of bacterial OM, and we used IL-10 knockout mice to test this hypothesis. Results: In wild-type mice, both Streptococcus pneumoniae and Haemophilus influenzae triggered the development of MCM in the middle ear mucosa. In IL-10 knockout mice, the number of goblet cells and mucin-producing cells in the middle ear was significantly reduced after bacterial middle ear infection compared with that in wild-type mice.
INTRODUCTION
Interleukin (IL)-10, produced by a variety of cells, including monocytes, macrophages, eosinophils, and bronchial epithelial cells, is a pleiotropic cytokine with proinflammatory and immunostimulatory effector functions 1-3 that contribute to disease pathogenesis. Overexpression of IL-10 in transgenic mice caused mucous cell metaplasia and hyperplasia (MCM), mucin up-regulation, inflammation, and tissue remodeling in the lung. 4 This finding prompted us to examine whether IL-10 plays a role in the MCM of otitis media (OM). It has been shown that IL-10 contributes to changes in the mucins and goblet cells in the colon 5 and that it plays a critical role in host resistance and survival in bacterial intestinal infection of mice. 6 On the other hand, IL-10 possesses anti-inflammatory, immunosuppressive, and tissue protective effects. 1, 3, 7 These effects are based upon inhibitory effects of IL-10 on many inflammatory cytokines, including interferon-gamma (IFN-γ), 8 vascular epithelial growth factor, 9 IL-1β, and IL-8. 10 During inflammation, macrophages rapidly produce proinflammatory cytokines such as tumor necrosis factor alpha, IL-1, and IL-12 in response to lipopolysaccharide or IFN-γ. Macrophages produce IL-10 after a burst of production of proinflammatory cytokines. Once IL-10 is produced, it suppresses immune responses and inflammatory reactions by suppressing the production of proinflammatory cytokines such as IL-1 or by reducing the cell surface expression of immunoreceptors such as major histocompatibility complex class II. 11 For this reason, IL-10 is being used in the clinic to treat patients with inflammatory bowel disease, rheumatoid arthritis, psoriasis, cystic fibrosis, and asthma, 2,12 aimed at the suppression of proinflammatory cytokine production in these chronic diseases.
The presence of IL-10 in middle ear effusion and mucosa is well documented in both human 13 and animal models. 14, 15 In the middle ear, pneumococcal infection causes up-regulation of numerous cytokines, [15] [16] [17] including IL-10, which is associated with MCM in the middle ear cavity. 18 We hypothesized that IL-10 plays a role in the MCM of OM.
MATERIALS AND METHODS
Animals. Approximately 4-to 6-week-old C57BL/ 6 wild-type (B6.129P2) mice and IL-10 knockout (B6.129P2-Il10 tm1Cgn /JIL10) mice were obtained from the Jackson Laboratory, Bar Harbor, Maine. They were bred and maintained in the animal facility at the University of Minnesota Medical School with the approval of the Institutional Animal Care and Use Committee. Mice homozygous for the Il-10 tm1Cgn targeted mutation are viable and fertile when housed under specific pathogen-free conditions. Under conventional housing conditions, homozygous mutant mice are small in size, are anemic, and have chronic enterocolitis. Their intestinal problems are far less severe (local inflammation of the proximal colon) in a pathogen-free environment. Lymphocyte development and antibody responses are normal in homozygous mutant mice. Rats had been shown to be useful for induction of MCM in the middle ear. 18, 19 Sprague-Dawley rats (weighing approximately 200 g) were therefore used as positive controls for MCM in this study. Mice were reportedly suitable for a model of acute OM, 20 but it is unknown whether mice were suitable for induction of MCM in the middle ear. Mice were selected because of their attractive genetic mutant models and available genome information.
Pathogens. Streptococcus pneumoniae type 6A (Pn6A), originally isolated from clinical OM, has been used for induction of OM in rats with a dose up to 2 × 10 9 colony-forming units (CFU) per milliliter in 50 μL of bacterial suspension (yielding approximately 10 7 CFU per bulla). 21 In mice, the inoculation dose was much lower than that in rats: approximately 2 × 10 2 or 2 × 10 3 CFU/mL in 10 μL of bacterial suspension (yielding approximately 10 to 100 CFU per bulla), as reported recently. 20 Pn6A was routinely refreshed on mice for maintenance of its virulence before bullar inoculation. Nontypeable Haemophilus influenzae (NTHi, strain 12) was a kind gift from Dr Stephen Barenkamp at the St Louis University School of Medicine, St Louis, Missouri. The inoculation dose was up to 2 × 10 9 CFU/mL in 50 μL of bacterial suspension (yielding approximately 10 7 CFU per bulla) for rats, and up to 10 8 CFU/mL 20 (ie, 2 × 10 6 CFU per bulla) for mice. All bacteria were suspended in phosphate-buffered saline solution (PBS).
Induction of OM. The animals were anesthetized with ketamine hydrochloride (80 mg/kg) and xylazine hydrochloride (16 mg/kg), and the bullae were surgically exposed via a ventral approach as previously described. 21 The inoculation volumes of bacterial suspension in mice and rats were 10 μL and 50 μL per bulla, respectively, and both bullae of each animal were inoculated. In dose-dependent studies of Pn6A, 3 to 6 wild-type mice were used for inoculation with doses from 2 × 10 2 to 2 × 10 9 CFU/mL. In dose-dependent studies of NTHi, 3 to 6 wild-type mice were used for inoculation with doses from 2 × 10 4 to 2 × 10 9 CFU/mL. Bullae with inoculation of NTHi at 2 × 10 9 CFU/mL, peptidoglycan-polysaccharide of Pn6A at 2 μg/mL served as experimental controls. The peptidoglycan-polysaccharide of Pn6A was prepared as previously described. 22 An additional 5 rats with PBS inoculation into the bullae served as blank controls. The animals were painlessly sacrificed on day 7 for harvest of the bullae and subsequent evaluation of pathological changes by hematoxylin and eosin (H & E) histology, Alcian blue-periodic acid-Schiff (AB-PAS) stain histochemistry, and mucin immunohistochemistry.
Histology. The bullae were fixed in 10% paraformaldehyde solution overnight, dehydrated in graded alcohol, immersed in xylene for 3 hours, embedded in paraffin, and cut at a thickness of 4 μm. The sections were deparaffinized in xylene, dehydrated in graded alcohol, and incubated with H & E for histology, AB-PAS for goblet cells, or specific antibody for mucin-producing cells, as previously described. 18 Goblet Cell Identification and Quantitation. Cells stained blue or purple by AB-PAS stain were identified as goblet cells. The AB-PAS-positive cells were viewed under a light microscope. Six areas in each bulla, as indicated in Fig 1A, were chosen for measurement of goblet cell numbers. Goblet cells were frequently found in these areas in response to challenge of bacteria in our pilot studies. Areas 1 to 3 constitute the superior part of the middle ear cavity, whereas areas 4 to 6 are the inferior part of the middle ear cavity.
Quantitative Analysis of Mucin-Producing Cells.
Goblet cells are specialized in mucin production. To verify their goblet cell identity, immunohistochemical analysis was performed on middle ear histologic sections as previously described, 23 with some modifications. The mucin polyclonal antibody used in this study was a custom-made, rabbit anti-rat middle ear mucin that reacted with multiple mucins and/or mucin-like molecules. Rat middle ear mucins were extracted by the method previously described. 24 Purified middle ear mucins were submitted to Animal Pharm Services Inc for production of polyclonal antibodies (antiserum). Rabbit antiserum with 1:200 dilution was incubated with middle ear sections for 90 minutes, washed, and incubated with secondary mouse anti-rabbit antibody conjugated to fluorescein isothiocyanate (Millipore). Mucin-producing cells were identified with the above polyclonal mu- cin antibody and analyzed quantitatively by counting. The results are presented as positive cell numbers per millimeter in length of the middle ear mucosa by the method previously described. 18 Six areas were taken for quantitative analysis of mucinproducing cells after bacterial challenges. The data are presented as mean ± SD. Statistical Analysis. Differences of data between groups were analyzed by nonpaired Student's t-test and/or analysis of variance, with p values of .05 considered statistically significant.
RESULTS
In gross examination of the bullar anatomy, there was no deformation in the middle ear of IL-10 knockout mice compared with that of control wildtype mice. There were no goblet cells in the middle ear mucosa and few in the orifice of the eustachian tube in both wild-type and IL-10 knockout mice before challenge with bacteria (data not shown). Hematoxylin and eosin histology was performed for evaluation of inflammatory cell infiltration, edema, and submucosal collagen deposition. It was demonstrated that inflammatory infiltration, edema, and submucosal deposition were remarkable in IL-10 knockout mice compared with those in wild-type mice. This finding suggests that inflammation and collagen metabolism in the middle ear mucosa are Mice were found to be quite susceptible to Pn6A infection. Six mice were inoculated with Pn6A (2 × 10 5 to 2 × 10 9 CFU/mL) bilaterally into the bullae, but all animals died on day 2 after the bullar inoculation because of the Pn6A virulence. All mice survived when NTHi was used in the range of 10 4 to 10 9 CFU/mL. Middle ear pathologic examination demonstrated that Pn6A at 10 7 CFU/mL or higher caused severe OM with partial necrosis of the middle ear epithelium (suggesting the cause of the animal deaths). Animals with bullar inoculation of Pn6A at 10 4 CFU/mL did not die on day 2, but were sick then and died on day 3 or 4. Doses of Pn6A at 2 × 10 2 CFU/mL in 9 mice and 10 3 CFU/mL in 9 mice were found to be appropriate. Six mice at each dose survived at least 8 days, and 3 mice died before the experiment ended and were excluded from this study. It was noted that the surviving animals were healthy on the day of sacrifice (day 7). Inoculation of PBS served as a control. The bullae were harvested for histochemistry. It was found that MCM was obvious in the middle ear mucosa of mice on day 7 after the Pn6A inoculation. Interestingly, there were no obvious differences in goblet cell numbers be-tween different doses of Pn6A inoculation (for 2 × 10 2 CFU/mL and 2 × 10 3 CFU/mL). The goblet cell numbers for NTHi at 2 × 10 9 CFU/mL were 25.3 ± 12.3 cells per high-power field (HPF), and were not significantly different from those for NTHi at 2 × 10 4 CFU/mL (19.3 ± 8.1 cells per HPF) and Pn6A at 10 2 CFU/mL (29.8 ± 13.1 cells per HPF) or Pn6A at 10 3 CFU/mL (30.9 ± 12.5 cells per HPF). The goblet cell numbers for Pn6A at 10 4 CFU/mL or higher were not applicable because of animal death. The goblet cell numbers for Pn6A at 10 2 were 13.4 ± 9.5, and those for Pn6A at 10 3 were 14.9 ± 8.5 (not significantly different).
Reduction of Goblet Cell Numbers in Mutant Mouse Middle Ear Mucosa Following Bacterial
Challenges. To determine whether IL-10 plays a role in MCM, we inoculated both bullae of 4 to 6 knockout mice and 4 to 6 wild-type mice with NTHi (2 × 10 9 CFU/mL) and Pn6A (2 × 10 2 CFU/mL). Staining with H & E and staining with AB-PAS were performed for evaluation of inflammatory cell infiltration and MCM, respectively. Staining with AB-PAS demonstrated significantly reduced goblet cell counts in the middle ears of IL-10 knockout mice (Fig 1D,F) compared with those in wild-type mice (Fig 1C,E) after challenge with Pn6A at 2 × 10 2 CFU/mL. Similar cell counts were observed in the group challenged with NTHi at 2 × 10 9 CFU/ mL (Fig 3) . 
Reduction of Mucin-Producing Cell Counts in Mutant Mouse Middle Ear Mucosa Following
Bacterial Challenges. Consistent with goblet cell counts, mucin antibody staining demonstrated that mucin-producing cells decreased in the middle ear mucosa of IL-10 knockout mice compared with those in the control ears after bacterial challenges with NTHi at 2 × 10 9 CFU/mL and Pn6A at 2 × 10 2 CFU/mL (Fig 4A,B) . Taking 6 locations in the middle ear into account as indicated in Fig 1A, there was a significant decrease of mucin-producing cells in the middle ear mucosa between mutant and wildtype mice (Fig 4C; 61.6 ± 10.7 cells per millimeter in wild-type mice versus 35.8 ± 10.2 cells per millimeter in mutant mice; p < .01). Similar cell counts from NTHi challenge were observed (see Fig 3B for Fig 1A) after challenge with Pn6A at 2 × 10 2 colony-forming units per milliliter. B) Density of mucin-producing cells in middle ear mucosa of wild-type mice after Pn6A challenge at same concentration. C) Difference in mucin-producing cells in middle ear mucosa between mutant (IL10KO) and wild-type (IL10WT) mice is significant (p < .01). comparison of mucin-producing cell numbers between NTHi and Pn6A). In PBS-inoculated middle ears, a few mucin-producing cells were identified ( Fig 3B) , whereas in non-inoculated middle ears, no mucin-producing cells were identified (data not shown). The number of mucin-producing cells following NTHi at 2 × 10 9 CFU/mL was 58.3 ± 11.2 cells per millimeter -not significantly different from the 55.6 ± 9.8 cells per millimeter following NTHi at 2 × 10 4 CFU/mL. The number of mucinproducing cells following Pn6A at 10 2 was 61.6 ± 10.7 cells per millimeter, and that following Pn6A at 10 3 CFU/mL was 65.7 ± 10.5 cells per millimeter; the count was not applicable for Pn6A at 10 4 CFU/ mL or higher because of animal deaths. The number of mucin-producing cells following Pn6A at 10 2 CFU/mL (35.8 ± 10.2 cells per millimeter) was not significantly different from that following Pn6A at 10 3 CFU/mL (38.9 ± 9.1 cells per millimeter). DISCUSSION A hallmark of OM is MCM that is accompanied by effusion rich in mucus (mucins). Infection induces infiltration of inflammatory cells and production of cytokines and chemokines. Cytokines and chemokines, in turn, trigger MCM; this is a classic pathway for triggering MCM in OM. The MCM is induced in acute OM, but is frequently exacerbated in chronic OM.
However, which cytokines are involved in MCM in the middle ear and which ones are not is not clear at the moment. We and others have shown that bacterial infection or cytokine challenge of middle ear mucosa results in MCM, 18, 19, 25 but whether these cytokines are essential for MCM has not been tested. Cytokines act as a net in response to bacterial challenges. It is very important to determine which cytokines or chemokines play an indispensable role in MCM in order to design innovative therapeutic interventions aimed at MCM in OM or other upper respiratory tract infectious diseases. Mutant mouse models are very useful for screening which cytokines or chemokines can be targeted in terms of controlling MCM in the middle ear under inflammatory conditions. In this study, we demonstrate that IL-10 is a potential target for prevention and treatment of MCM.
Regarding the receptor for bacterium-induced MCM, toll-like receptor 2 (TLR2) may mediate the Pn6A-induced response. It has been shown that TLR2 is required for recognition of peptidoglycan and that it mediates the production of cytokines IL-6 and TNF-α. 26 In our recent studies, peptidoglycan-polysaccharide regulated the expression of TLR2 (data not shown). Generally speaking, bacterial lipoproteins are powerful in the induction of many cytokines. 27 Production of IL-10 is mainly induced by lipoproteins such as outer surface protein A (OspA), and lipopolysaccharide is much less powerful than OspA for induction of IL-10 in macrophages. 28 Lipoprotein of Pn6A may stimulate the production of IL-10 via TLR2. Since IL-10 is one of the important cytokines in immune and inflammatory responses and is part of the cytokine network, IL-10 is regulated by other inflammatory mediators such as TNFα. 29, 30 This raises the question of whether TNF-αinduced MCM occurs via IL-10. This needs to be clarified in future studies.
Toll-like receptor 4 (TLR4) may be involved in the NTHi-induced response, because the pathogenassociated molecular pattern in a gram-negative cell wall component (namely, lipopolysaccharide) interacts with TLR4, yielding signal transduction for immune and inflammatory responses in many cell types. 26 However, our pilot study indicated that MCM occurred in TLR4 knockout mice after bacterial challenges with either Pn6A or NTHi (data not shown). This finding suggests that TLR4 is not essential for MCM in bacterial OM, although it may participate in mediating goblet cell metaplasia and hyperplasia in bacterial middle ear infections. Noncell wall components produced during bacterial infection may play a role in MCM.
At the post-receptor level, many signaling pathways may be involved in the regulation of IL-10 in middle ear mucosa with bacterial infection. Signals leading to activation of STAT3 (signal transducer and activator of transcription 3; instead of nuclear factor κB) are involved in the regulatory control of IL-10 production in humans. 31 Analysis of the human IL-10 promoter sequence revealed the binding site for STAT3, 31 verifying that STAT3 regulates the expression of IL-10. Whether bacterial infection in the middle ear mucosa leads to activation of STAT3 and then IL-10 production warrants future investigation. CONCLUSIONS We conclude from this study that IL-10 plays an important role in MCM in the middle ear mucosa in response to middle ear bacterial infection through a classic pathway in which infection leads to inflammatory cell infiltration, which leads to cytokine release, which leads to MCM. Further studies are needed to determine whether IL-10 is a target for the treatment of MCM in OM.
